breakthrough Therapy Archives -

AstraZeneca and Daiichi Sankyo have claimed a fifth breakthrough designation from the FDA for Enhertu, shortly after showing

Enhertu gets breakthrough tag in HER2-low breast cancer

https://pharmaphorum.com/news/enhertu-gets-breakthrough-tag-in-her2-low-breast-cancer/

Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC)

FDA gives Daiichi Sankyo’s HER3 drug a breakthrough tag

https://pharmaphorum.com/news/fda-gives-daiichi-sankyos-her3-lung-cancer-drug-breakthrough-tag/

Hard on the heels of impressive new data for Enhertu as a second-line therapy for breast cancer, AstraZeneca

Enhertu nabs speedy FDA review for earlier use in breast cancer

https://pharmaphorum.com/news/enhertu-nabs-speedy-fda-review-for-earlier-use-in-breast-cancer/

Alnylam is to forge ahead with a rare disease therapy on its own after Sanofi decided to opt

Sanofi passes on Alnylam’s breakthrough therapy

https://pharmaphorum.com/news/sanofi-passes-alnylams-breakthrough-therapy/

Disease education to resonate with patient & provider

Innovative Regulatory Pathways Summit

https://pharmaphorum.com/events/innovative-regulatory-pathways-summit-2/

breakthrough Therapy